Logo image of VET

VERMILION ENERGY INC (VET) Stock Fundamental Analysis

NYSE:VET - CA9237251058 - Common Stock

7.49 USD
0 (0%)
Last: 9/4/2025, 4:15:00 PM
7.49 USD
0 (0%)
After Hours: 9/4/2025, 4:15:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VET. VET was compared to 209 industry peers in the Oil, Gas & Consumable Fuels industry. Both the profitability and financial health of VET have multiple concerns. VET does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

VET had negative earnings in the past year.
In the past year VET had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: VET reported negative net income in multiple years.
VET had a positive operating cash flow in each of the past 5 years.
VET Yearly Net Income VS EBIT VS OCF VS FCFVET Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B

1.2 Ratios

VET has a worse Return On Assets (-2.76%) than 73.21% of its industry peers.
VET's Return On Equity of -6.87% is on the low side compared to the rest of the industry. VET is outperformed by 70.81% of its industry peers.
VET's Return On Invested Capital of 3.41% is on the low side compared to the rest of the industry. VET is outperformed by 65.55% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for VET is significantly below the industry average of 21.91%.
The 3 year average ROIC (10.72%) for VET is well above the current ROIC(3.41%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -2.76%
ROE -6.87%
ROIC 3.41%
ROA(3y)4.74%
ROA(5y)-0.65%
ROE(3y)9.7%
ROE(5y)-15.85%
ROIC(3y)10.72%
ROIC(5y)N/A
VET Yearly ROA, ROE, ROICVET Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

VET has a Operating Margin of 13.76%. This is comparable to the rest of the industry: VET outperforms 45.45% of its industry peers.
VET's Operating Margin has improved in the last couple of years.
The Gross Margin of VET (67.97%) is better than 76.08% of its industry peers.
In the last couple of years the Gross Margin of VET has remained more or less at the same level.
Industry RankSector Rank
OM 13.76%
PM (TTM) N/A
GM 67.97%
OM growth 3Y-29.16%
OM growth 5Y2.82%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.52%
GM growth 5Y0.95%
VET Yearly Profit, Operating, Gross MarginsVET Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), VET is creating some value.
VET has less shares outstanding than it did 1 year ago.
VET has less shares outstanding than it did 5 years ago.
VET has a worse debt/assets ratio than last year.
VET Yearly Shares OutstandingVET Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
VET Yearly Total Debt VS Total AssetsVET Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

Based on the Altman-Z score of 0.44, we must say that VET is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.44, VET is doing worse than 64.11% of the companies in the same industry.
A Debt/Equity ratio of 0.74 indicates that VET is somewhat dependend on debt financing.
The Debt to Equity ratio of VET (0.74) is worse than 62.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z 0.44
ROIC/WACC0.37
WACC9.31%
VET Yearly LT Debt VS Equity VS FCFVET Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

VET has a Current Ratio of 1.94. This is a normal value and indicates that VET is financially healthy and should not expect problems in meeting its short term obligations.
VET has a Current ratio of 1.94. This is in the better half of the industry: VET outperforms 74.64% of its industry peers.
A Quick Ratio of 1.84 indicates that VET should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.84, VET is in the better half of the industry, outperforming 76.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.84
VET Yearly Current Assets VS Current LiabilitesVET Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.38% over the past year.
The Revenue has decreased by -2.71% in the past year.
The Revenue has been growing slightly by 1.65% on average over the past years.
EPS 1Y (TTM)76.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190.38%
Revenue 1Y (TTM)-2.71%
Revenue growth 3Y-2.42%
Revenue growth 5Y1.65%
Sales Q2Q%-3.89%

3.2 Future

The Earnings Per Share is expected to grow by 17.68% on average over the next years. This is quite good.
VET is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.20% yearly.
EPS Next Y376.07%
EPS Next 2Y19.49%
EPS Next 3Y17.68%
EPS Next 5YN/A
Revenue Next Year-0.72%
Revenue Next 2Y-9.87%
Revenue Next 3Y1.21%
Revenue Next 5Y1.2%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
VET Yearly Revenue VS EstimatesVET Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
VET Yearly EPS VS EstimatesVET Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VET reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VET. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VET Price Earnings VS Forward Price EarningsVET Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

84.21% of the companies in the same industry are more expensive than VET, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.64
VET Per share dataVET EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

VET's earnings are expected to grow with 17.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.49%
EPS Next 3Y17.68%

More info and screens

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 4.83%, VET is a good candidate for dividend investing.
VET's Dividend Yield is a higher than the industry average which is at 6.06.
Compared to an average S&P500 Dividend Yield of 2.32, VET pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.83%

5.2 History

The dividend of VET decreases each year by -28.87%.
VET has been paying a dividend for at least 10 years, so it has a reliable track record.
VET has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-28.87%
Div Incr Years2
Div Non Decr Years2
VET Yearly Dividends per shareVET Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

VET has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-41.15%
EPS Next 2Y19.49%
EPS Next 3Y17.68%
VET Yearly Income VS Free CF VS DividendVET Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B -1B -1.5B

More info and screens

VERMILION ENERGY INC

NYSE:VET (9/4/2025, 4:15:00 PM)

After market: 7.49 0 (0%)

7.49

0 (0%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners50.53%
Inst Owner Change2.37%
Ins Owners0.58%
Ins Owner ChangeN/A
Market Cap1.15B
Analysts72
Price Target10.02 (33.78%)
Short Float %11.16%
Short Ratio18.09
Dividend
Industry RankSector Rank
Dividend Yield 4.83%
Yearly Dividend0.34
Dividend Growth(5Y)-28.87%
DP-41.15%
Div Incr Years2
Div Non Decr Years2
Ex-Date09-29 2025-09-29 (0.13)
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-913.49%
Min EPS beat(2)-1768.81%
Max EPS beat(2)-58.17%
EPS beat(4)0
Avg EPS beat(4)-494.72%
Min EPS beat(4)-1768.81%
Max EPS beat(4)-27.39%
EPS beat(8)0
Avg EPS beat(8)-391.32%
EPS beat(12)3
Avg EPS beat(12)1293.67%
EPS beat(16)5
Avg EPS beat(16)959.91%
Revenue beat(2)0
Avg Revenue beat(2)-15.59%
Min Revenue beat(2)-26.83%
Max Revenue beat(2)-4.34%
Revenue beat(4)0
Avg Revenue beat(4)-11.56%
Min Revenue beat(4)-26.83%
Max Revenue beat(4)-4.34%
Revenue beat(8)0
Avg Revenue beat(8)-12.87%
Revenue beat(12)1
Avg Revenue beat(12)-8.03%
Revenue beat(16)5
Avg Revenue beat(16)1.76%
PT rev (1m)1.09%
PT rev (3m)-8.56%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)-90.38%
EPS NY rev (1m)211.4%
EPS NY rev (3m)211.4%
Revenue NQ rev (1m)-6.28%
Revenue NQ rev (3m)5.63%
Revenue NY rev (1m)-10.84%
Revenue NY rev (3m)-18.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.83
P/FCF N/A
P/OCF 2.07
P/B 0.59
P/tB 0.59
EV/EBITDA 3.64
EPS(TTM)-0.87
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-4.45
FCFYN/A
OCF(TTM)3.62
OCFY48.32%
SpS9.03
BVpS12.69
TBVpS12.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.76%
ROE -6.87%
ROCE 4.32%
ROIC 3.41%
ROICexc 3.45%
ROICexgc 3.45%
OM 13.76%
PM (TTM) N/A
GM 67.97%
FCFM N/A
ROA(3y)4.74%
ROA(5y)-0.65%
ROE(3y)9.7%
ROE(5y)-15.85%
ROIC(3y)10.72%
ROIC(5y)N/A
ROICexc(3y)10.81%
ROICexc(5y)N/A
ROICexgc(3y)10.81%
ROICexgc(5y)N/A
ROCE(3y)13.57%
ROCE(5y)N/A
ROICexcg growth 3Y-31.83%
ROICexcg growth 5Y4.7%
ROICexc growth 3Y-31.83%
ROICexc growth 5Y4.7%
OM growth 3Y-29.16%
OM growth 5Y2.82%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.52%
GM growth 5Y0.95%
F-Score6
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA 2.07
Cap/Depr 243.19%
Cap/Sales 89.36%
Interest Coverage 2.26
Cash Conversion 79.35%
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.84
Altman-Z 0.44
F-Score6
WACC9.31%
ROIC/WACC0.37
Cap/Depr(3y)126.62%
Cap/Depr(5y)107.23%
Cap/Sales(3y)33.7%
Cap/Sales(5y)32.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190.38%
EPS Next Y376.07%
EPS Next 2Y19.49%
EPS Next 3Y17.68%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.71%
Revenue growth 3Y-2.42%
Revenue growth 5Y1.65%
Sales Q2Q%-3.89%
Revenue Next Year-0.72%
Revenue Next 2Y-9.87%
Revenue Next 3Y1.21%
Revenue Next 5Y1.2%
EBIT growth 1Y11.23%
EBIT growth 3Y-30.87%
EBIT growth 5Y4.51%
EBIT Next Year102.66%
EBIT Next 3Y12.45%
EBIT Next 5Y15.47%
FCF growth 1Y-237.3%
FCF growth 3Y0.4%
FCF growth 5Y4.86%
OCF growth 1Y-48.97%
OCF growth 3Y5.06%
OCF growth 5Y3.28%